SYS-CON MEDIA Authors: Kevin Benedict, Jason Bloomberg, David H Deans, RealWire News Distribution, Gilad Parann-Nissany

News Feed Item

Investigation Report on China's Tiotropium Bromide Market, 2009-2018

 

DUBLIN, Mar. 28, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/8gxjqj/investigation) has announced the addition of the "Investigation Report on China's Tiotropium Bromide Market, 2009-2018" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

As the air becomes more contaminated, incidence of asthma and chronic obstructive pulmonary diseases also increases. Consequently, more market space is provided for relevant drug manufacturers.

Asthma is a common multiple disease mainly caused by inheritance and environment factors. Recurrent attacks of asthma can lead to complications such as chronic obstructive pulmonary disease, emphysema, cor pulmonale, heart failure and respiratory failure. Sometimes it can endanger patients' lives.

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease that is not fully reversible. It includes chronic bronchitis and emphysema. Pathogens include smoking, air pollution, small airway infection and pneumoconiosis. There are approximately 600 million people worldwide suffering from chronic obstructive pulmonary diseases. According to WHO, COPD is the fourth biggest killer among diseases worldwide. It ranks the same with AIDS after heart diseases, cerebrovascular diseases and acute pulmonary infection. There are over 200 million COPD patients in the world now, and its mortality rate continues to rise year after year. More than 3 million people die of this disease every year with 1.2 million of them in China.

As patients of asthma and chronic obstructive pulmonary disease become more, demand of the medication worldwide also grows steeply. Developed by Boehringer Ingelheim Group with the trade name ""Spiriva"", tiotropium bromide was approved in the Netherlands and Philippines for the first time in June 2002. It was approved to China in 2006. Global sales revenue of Spiriva in 2012 was USD 4.71 billion, increased by 13% YOY.

According to CRI's market investigation, the CAGR of sales revenue of tiotropium bromide in China sample hospital market is more than 70% from 2007 to 2012. Most market share was seized by Boehringer Ingelheim Group followed by Chia Tai Tianqing Pharmaceutical, which totally added up to over 90% of the market. Besides Spiriva from Boehringer Ingelheim Group, four Chinese pharmaceutical manufacturers have received production approval.

Industrial development and lack of environmental concern have led to serious air contamination in China. Incidence of COPD in China is predicted to keep increasing, leading to increasing demand of relevant medication. Anticipation shows that market size of tiotropium bromide in China will keep expanding rapidly in the next few years.


Key Topics Covered:

1 Relevant Concepts of Tiotropium Bromide

2 Market Overview of Tiotropium Bromide in China, 2009-2013

3 Investigation on Sales Value of Tiotropium Bromide in China, 2009-2013

4 Investigation on Market Share of Major Tiotropium Bromide Manufacturers in China, 2009-2013

5 Investigation on Market Size of Tiotropium Bromide by Dosage Form in China, 2009-2013

6 Reference Price of Tiotropium Bromide Produced by Different Enterprises in China Hospital Market

7 Major Manufacturing Enterprises in China Tiotropium Bromide Market, 2009-2014

8 Prospect of China Tiotropium Bromide Market, 2014-2018


Companies Mentioned:

  • Boehringer Ingelheim
  • Chia Tai Tianqing Pharmaceutical Group
  • Zhejiang Xianju Pharmaceutical


For more information visit http://www.researchandmarkets.com/research/8gxjqj/investigation


Media Contact: Laura Wood , +353-1-481-1716, [email protected]


 

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.